Merck KGaA (MRK) PT Set at €100.00 by JPMorgan Chase & Co.

Merck KGaA (FRA:MRK) has been assigned a €100.00 ($116.28) target price by stock analysts at JPMorgan Chase & Co. in a report released on Tuesday. The firm presently has a “neutral” rating on the healthcare company’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 4.49% from the company’s previous close.

Several other equities research analysts have also recently issued reports on the company. Morgan Stanley set a €90.00 ($104.65) price target on Merck KGaA and gave the company a “neutral” rating in a research note on Monday. DZ Bank reiterated a “neutral” rating on shares of Merck KGaA in a research note on Monday. Kepler Capital Markets set a €108.00 ($125.58) price target on Merck KGaA and gave the company a “buy” rating in a research note on Wednesday, February 6th. Sanford C. Bernstein set a €105.00 ($122.09) price objective on shares of Merck KGaA and gave the company a “buy” rating in a research report on Tuesday, February 5th. Finally, Nord/LB set a €80.00 ($93.02) price objective on shares of Merck KGaA and gave the company a “sell” rating in a research report on Thursday, January 24th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of €98.80 ($114.88).

Shares of MRK stock opened at €95.70 ($111.28) on Tuesday. Merck KGaA has a 1 year low of €76.60 ($89.07) and a 1 year high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

See Also: How a Put Option Works

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply